SUTRO BIOPHARMA INC. - COMMON STOCK

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

10 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

13 11 2024 15:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

01 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

10 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 9 2024 15:01:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

14 9 2024 02:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

11 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

22 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 8 2024 15:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

09 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 5 2024 15:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

30 4 2024 07:00:01 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

02 4 2024 05:18:56 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

25 3 2024 15:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

06 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

04 1 2024 15:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

14 12 2023 15:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

11 12 2023 15:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

04 12 2023 15:05:00 提供 Nasdaq GlobeNewswire